Observational Study of Acalabrutinib in Patients with Chronic Lymphocytic Leukaemia in the United Kingdom

Trial Identifier: D8220R00033
Sponsor: AstraZeneca
Collaborator:
UKCLL Forum
Start Date: October 2022
Primary Completion Date: April 2027
Study Completion Date: April 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United Kingdom Aylesbury, United Kingdom
United Kingdom Bath, United Kingdom
United Kingdom Birmingham, United Kingdom
United Kingdom Bournemouth, United Kingdom
United Kingdom Cardiff, United Kingdom
United Kingdom Cornwall, United Kingdom
United Kingdom Dartford, United Kingdom
United Kingdom Derby, United Kingdom
United Kingdom Doncaster, United Kingdom
United Kingdom Dorset, United Kingdom
United Kingdom Eastbourne, United Kingdom
United Kingdom Hull, United Kingdom
United Kingdom Leicester, United Kingdom
United Kingdom Lincoln, United Kingdom
United Kingdom Liverpool, United Kingdom
United Kingdom London, United Kingdom, W12 OHS
United Kingdom London, United Kingdom, SE1 9RT
United Kingdom Mid Yorkshire, United Kingdom
United Kingdom Middlesborough, United Kingdom
United Kingdom Newcastle, United Kingdom
United Kingdom North Shields, United Kingdom
United Kingdom Norwich, United Kingdom
United Kingdom Nottingham, United Kingdom
United Kingdom Oxford, United Kingdom
United Kingdom Plymouth, United Kingdom
United Kingdom Southampton, United Kingdom
United Kingdom Stockton on Tees, United Kingdom
United Kingdom Stoke on Trent, United Kingdom
United Kingdom Wigan, United Kingdom